2024
Association Between Hypertensive Disorders of Pregnancy and Interval Neurocognitive Decline
Elfassy T, Kulandavelu S, Dodds L, Mesa R, Rundek T, Sharashidze V, Paidas M, Daviglus M, Kominiarek M, Stickel A, Perreira K, Kobayashi M, Garcia T, Isasi C, Lipton R, González H. Association Between Hypertensive Disorders of Pregnancy and Interval Neurocognitive Decline. Obstetrics And Gynecology 2024, 143: 785-793. PMID: 38574370, PMCID: PMC11098694, DOI: 10.1097/aog.0000000000005571.Peer-Reviewed Original ResearchConceptsCognitive declineHypertensive disorders of pregnancyNeurocognitive assessmentDisorders of pregnancyAssociated with decreased processing speedBrief-Spanish English Verbal Learning TestSpanish English Verbal Learning TestDigit symbol substitution scoresVerbal Learning TestDigit symbol substitutionNeurocognitive declineAssociated with cognitive declineHypertensive disordersGestational hypertensionFollow-up timeFunction of cognitionWord fluencyExecutive functionNeurocognitive differencesLearning TestCognitive domainsSymbol substitutionCognitive functionProcessing speedSelf-Report
2023
Epigenetic age acceleration as a biomarker for impaired cognitive abilities in adulthood following early life adversity and psychiatric disorders
Felt J, Yusupov N, Harrington K, Fietz J, Zhang Z, Sliwinski M, Ram N, O'Donnell K, Group B, Meaney M, Putnam F, Noll J, Binder E, Shenk C. Epigenetic age acceleration as a biomarker for impaired cognitive abilities in adulthood following early life adversity and psychiatric disorders. Neurobiology Of Stress 2023, 27: 100577. PMID: 37885906, PMCID: PMC10597797, DOI: 10.1016/j.ynstr.2023.100577.Peer-Reviewed Original ResearchEarly life adversityPsychiatric disordersEpigenetic age accelerationLife adversityAge accelerationProspective cohort studyBiological agingNon-abused controlsCohort studyNeurocognitive screeningPeripheral bloodCommunity cohortNeurocognitive declineIndependent cohortCognitive declineEarly screeningMental disordersCohortGrimAge clockDisordersBiomarkersLower general cognitive abilityEarly declineNeurocognitive abilitiesCognitive abilitiesPsychosocial risk factors and cognitive decline in people living with HIV: results from the Malaysian HIV and aging (MHIVA) study
Neelamegam M, Ahmad A, Chong M, Wong P, Zulhaimi N, Cysique L, Earnshaw V, Omar S, Kamarulzaman A, Kamaruzzaman S, Rajasuriar R. Psychosocial risk factors and cognitive decline in people living with HIV: results from the Malaysian HIV and aging (MHIVA) study. AIDS Care 2023, 36: 1041-1049. PMID: 37666210, PMCID: PMC10909927, DOI: 10.1080/09540121.2023.2254543.Peer-Reviewed Original ResearchPsychosocial risk factorsRisk factorsMalaysian HIVMoCA scoresCognitive functionMean MoCA scoreMontreal Cognitive AssessmentSocial isolationDepression Anxiety Stress Scale-21Lubben Social Network Scale-6Anxiety Stress Scale-21Stress Scale-21Antiretroviral therapyMedian ageStable ARTHIV parametersNeurocognitive declineSevere depressionNeurocognitive impairmentPsychosocial factorsCognitive declineHIVSevere anxietyPLWHSevere stress
2022
Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.
Huntoon K, Anderson S, Ballman K, Twohy E, Dooley K, Jiang W, An Y, Li J, von Roemeling C, Qie Y, Ross O, Cerhan J, Whitton A, Greenspoon J, Parney I, Ashman J, Bahary J, Hadjipanayis C, Urbanic J, Farace E, Khuntia D, Laack N, Brown P, Roberge D, Kim B. Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. Neuro-Oncology 2022, 25: 1123-1131. PMID: 36472389, PMCID: PMC10237411, DOI: 10.1093/neuonc/noac262.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyStereotactic radiosurgeryBrain metastasesRadiation therapyNeurocognitive declineSerum levelsRadiation-induced neurocognitive declinePretreatment serum markersLow serum levelsAssociated with neurocognitive impairmentRandomized clinical trialsEnzyme-linked immunosorbent assaySurgical resectionSecondary endpointsSerum markersRetrospective analysisClinical trialsNeurocognitive impairmentCognitive impairmentMetastasisBlood samplesImmunosorbent assayMonthsSecondary analysisTherapyPractice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy
Jairam V, Park HS, Yu JB, Bindra RS, Contessa JN, Jethwa KR. Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy. Advances In Radiation Oncology 2022, 7: 100949. PMID: 35521071, PMCID: PMC9065721, DOI: 10.1016/j.adro.2022.100949.Peer-Reviewed Original ResearchWhole-brain radiation therapyBrain radiation therapyRadiation oncologistsPractice patternsRadiation therapyHA-WBRTNeurocognitive declineCommon reasonHippocampal avoidance whole brain radiation therapyNational practice patternsDeleterious cognitive effectsRoutine clinical practiceNeurocognitive preservationBrain metastasesTreatment delayProvider characteristicsEffective treatmentCurrent evidencePearson χMemantineClinical practicePatientsPrior authorizationMajority of respondentsTherapy
2021
Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy
Jairam V, Park H, Yu J, Bindra R, Contessa J, Jethwa K. Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e569. DOI: 10.1016/j.ijrobp.2021.07.1536.Peer-Reviewed Original ResearchWhole-brain radiation therapyWhole brain radiotherapyRadiation oncologistsPractice patternsBrain radiotherapyWBRT patientsNeurocognitive declineRadiation therapyCommon reasonCurrent evidenceHippocampal-avoidance whole-brain radiotherapyN-methyl-D-aspartate receptor antagonistConventional whole brain radiotherapyBrain radiation therapyNational practice patternsDeleterious cognitive effectsRoutine clinical practiceT-testMATERIAL/METHODSStudent's t-testMost radiation oncologistsIntracranial controlNeurocognitive preservationBrain metastasesMedication costs
2017
Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?
Justice AC, Erlandson KM, Hunt P, Landay A, Miotti P, Tracy RP. Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era? The Journal Of Infectious Diseases 2017, 217: 521-528. PMID: 29165684, PMCID: PMC5853399, DOI: 10.1093/infdis/jix586.Peer-Reviewed Original ResearchConceptsHIV infectionLong-term treatment toxicityAntiretroviral therapy eraChronic HIV infectionLow-level inflammationT-cell countsForms of cancerART initiationTherapy eraTreatment toxicityImmune dysfunctionRenal diseaseLiver diseaseChronic inflammationIntervention trialsClinical managementNeurocognitive declineCardiovascular diseaseClinical trialistsUninfected individualsRNA suppressionHIV researchWeight gainTranslational scientistsBiomarkers
2006
Transcerebral Platelet Activation After Aortic Cross-Clamp Release is Linked to Neurocognitive Decline
Mathew JP, Rinder HM, Smith BR, Newman MF, Rinder CS. Transcerebral Platelet Activation After Aortic Cross-Clamp Release is Linked to Neurocognitive Decline. The Annals Of Thoracic Surgery 2006, 81: 1644-1649. PMID: 16631650, DOI: 10.1016/j.athoracsur.2005.12.070.Peer-Reviewed Original ResearchConceptsCross-clamp removalAortic cross-clamp removalCardiopulmonary bypassPlatelet activationNeurocognitive injuryCognitive deficitsNeurocognitive declineElective coronary artery bypass graft surgeryCoronary artery bypass graft surgeryAortic cross-clamp releaseArtery bypass graft surgeryBypass graft surgeryCross-clamp releaseSubset of patientsVenous blood samplesJugular venous blood samplesJugular venous bloodCPB patientsGraft surgeryCardiac surgeryPatient subsetsInjury scoreAortic archVenous bloodCognitive injury
2001
Platelet PlA2 polymorphism enhances risk of neurocognitive decline after cardiopulmonary bypass
Mathew J, Rinder C, Howe J, Fontes M, Crouch J, Newman M, Phillips-Bute B, Smith B, Group T. Platelet PlA2 polymorphism enhances risk of neurocognitive decline after cardiopulmonary bypass. The Annals Of Thoracic Surgery 2001, 71: 663-666. PMID: 11235724, DOI: 10.1016/s0003-4975(00)02335-3.Peer-Reviewed Original ResearchConceptsMini-Mental State ExaminationPlA1/A1PlA1/A2Cardiopulmonary bypassNeurocognitive declinePlA2 polymorphismPlatelet GPIIIaState ExaminationBaseline Mini-Mental State ExaminationGreater neurocognitive declineProthrombotic genetic factorsPostoperative day 4Prothrombotic risk factorsEmbolic insultFrequent complicationPlA2 allelePlaque embolizationLocal thrombosisRisk factorsThrombotic processCardiovascular settingsPlA2 genotypeNeurocognitive changesDay 4Multivariate analysis
1996
CT measurement of suprasellar cistern predicts rate of cognitive decline in Alzheimer's disease
Aylward E, Rasmusson D, Brandt J, Raimundo L, Folstein M, Pearlson G. CT measurement of suprasellar cistern predicts rate of cognitive decline in Alzheimer's disease. Journal Of The International Neuropsychological Society 1996, 2: 89-95. PMID: 9375193, DOI: 10.1017/s135561770000093x.Peer-Reviewed Original ResearchConceptsSuprasellar cisternAlzheimer's diseaseAD patientsCT measuresQuantitative computed tomography (CT) measuresMini-Mental State Exam scoreCT measurementsComputed tomography measuresProbable Alzheimer's diseaseState Exam scoreBicaudate ratioBifrontal ratioNeurocognitive declineLateral ventricleThird ventricleCT scanTomography measuresCognitive declineCognitive functionPatientsAdaptive functioningDiseaseScansNeuropsychological measuresCognitive functioning
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply